1. Pink Sheet
  2. >>Biosimilars & Generics

Lyrica Generics Likely Delayed By A Pfizer Labeling Supplement

 
• By Derrick Gingery

US FDA's last-minute approval may have allowed Pfizer three more weeks of sales without competition.

stopping the Dominio effect
A labeling update approved just before patent expiry may have caused Lyrica generics to be cleared later than expected in the US . • Source: Shutterstock

An well-timed labeling update by Lyrica sponsor Pfizer Inc. appears to have allowed the company to squeeze a few more days of monopoly conditions out of the product in the US before generic competition arrived.

Patent protection on Lyrica (pregabalin) was set to expire 30 June and nine generic companies were ready with competitors. But US Food and Drug Administration approval appears to have been delayed by two supplements that forced the generics to update their labels

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Biosimilars & Generics

EU Biosimilar Filings, Opinions And Approvals

 
• By Neena Brizmohun

A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.

Pulling Together: Global Regulators Discuss Convergence On Biosimilars

 
• By Dave Wallace

While the biosimilars industry has welcomed individual pockets of progress around regulatory streamlining, it is essential that approaches from global authorities move forward together if they are to have a meaningful impact on biosimilar development. At Medicines for Europe’s annual biosimilars conference, regulators from around the world talked about how their thinking is converging.

Beyond Tariffs: The Silver Lining Of The US Pharma Security Investigation

 
• By Jessica Merrill

An investigation by the US Secretary of Commerce into pharmaceutical imports gives industry an opportunity to comment. AAM CEO John Murphy talked to Pink Sheet's sister publication Scrip about the latest developments.